Jane E Bailly

US Patent:

20080096264, Apr 24, 2008

Filed:

Apr 17, 2007

Appl. No.:

11/785364

Inventors:

Brian Murphy - Bethesda MD, US
Peter Collins - Bethesda MD, US
Anna Durbin - Takoma Park MD, US
Mario Skiadopoulos - Potomac MD, US
Tao Tao - Bethesda MD, US
Alexander Schmidt - Bethesda MD, US
Jane Bailly - Sunnyvale CA, US

Assignee:

The Government of the US, Represented by the Secretary, Dept. of Health & Human Services - Rockville MD

International Classification:

C12N 7/00
C07H 21/04

US Classification:

435235100, 536023720

Abstract:

The invention provides isolated nucleic acids encoding recombinant genomes or antigenomes of Human Parainfluenza Viruses that are useful as vaccines. The recombinant genomes or antigenomes can be incorporated into expression vectors for production of recombinant viruses in vitro. The invention also provides recombinant Human Parainfluenza viruses having one or more mutations that attenuate replication of the virus in a host.

US Patent:

7201907, Apr 10, 2007

Filed:

Jun 1, 2000

Appl. No.:

09/586479

Inventors:

Alexander C. Schmidt - Berlin, DE
Mario H. Skiadopoulos - Potomac MD, US
Peter L. Collins - Kensington MD, US
Brian R. Murphy - Bethesda MD, US
Jane E. Bailly - Mountain View CA, US
Anna P. Durbin - Takoma Park MD, US

Assignee:

The United States of America, Represented by the Secretary, Department of Health and Human Services - Washington DC

International Classification:

A61K 39/12
A61K 39/155

US Classification:

4241991, 4242111, 435 691, 536 2372

Abstract:

Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response or as vectors for introducing heterologous genes into a host. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different PIV virus to form the human-bovine chimeric PIV genome or antigenome.